Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The structure of Leptospira interrogans GAPDH sheds light into an immunoevasion factor that can target the anaphylatoxin C5a of innate immunity

  • Navas-Yuste, Sergio
  • De la Paz-García, Karla
  • Querol-García, Javier
  • Gómez, Sara
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
15 p.-7 fig.-4 tab., Leptospirosis is a neglected worldwide zoonosis involving farm animals and domestic pets caused by the Gram-negative spirochete Leptospira interrogans.This bacterium deploys a variety of immune evasive mechanisms, some of them targeted at the complement system of the host’s innate immunity. In this work, we have solved the X-ray crystallographic structure of L. interrogans glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to 2.37-Å resolution, a glycolytic enzyme that has been shown to exhibit moonlighting functions that potentiate infectivity and immune evasion in various pathogenic organisms.Besides, we have characterized the enzyme’s kinetic parameters toward the cognate substrates and have proven that the two natural products anacardic acid and curcumin are able to inhibit L. interrogans GAPDH at micromolar concentration through a noncompetitive inhibition modality. Furthermore, we have established that L. interrogans GAPDH can interact with the anaphylatoxin C5a of human innate immunity in vitro using bio-layer interferometry and a short-range cross-linking reagent that tethers free thiol groups in protein complexes. To shed light into the interaction between L. interrogans GAPDH and C5a, we have also carried out cross-link guided protein-protein docking. These results suggest that L. interrogans could be placed in the growing list of bacterial pathogens that exploit glycolytic enzymes as extracellular immune evasive factors. Analysis of the docking results indicates a low affinity interaction that is consistent with previous evidence, including known binding modes of other a-helical proteins with GAPDH. These findings allow us to propose L. interrogans GAPDH as a potential immune evasive factor targeting the complement system., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-B-I00 (to MCV) and PID2019-104912RB-I00 (to SRdC); and the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00. It was also funded by Grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to SRdC and MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). SRdC was also supported by the CIBER de Enfermedades Raras. KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural biology of complement receptors

  • Santos-López, Jorge
  • De la Paz-García, Karla
  • Fernández, Francisco J.
  • Vega, María Cristina
25 p.-6 fig.-1 tab., The complement system plays crucial roles in a wide breadth of immune and inflammatory processes and is frequently cited as an etiological or aggravating factor in many human diseases, from asthma to cancer. Complement receptors encompass at least eight proteins from four structural classes, orchestrating complement-mediated humoral and cellular effector responses and coordinating the complex cross-talk between innate and adaptive immunity.The progressive increase in understanding of the structural features of the main complement factors, activated proteolytic fragments, and their assemblies have spurred a renewed interest in deciphering their receptor complexes. In this review, we describe what is currently known about the structural biology of the complement receptors and their complexes with natural agonists and pharmacological antagonists. We highlight the fundamental concepts and the gray areas where issues and problems have been identified, including current research gaps. We seek to offer guidance into the structural biology of the complement system as structural information underlies fundamental and therapeutic research endeavors. Finally, we also indicate what we believe are potential developments in the field., This work was funded by Grants PDC2022-133713-I00 of the Spanish Ministerio de Ciencia e Innovación-Recovery,Transformation and Resilience Plan (PRTR), S2022/BMD-7278 of the Regional Government of Madrid, and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Network of Excellence Complement in Health and Disease (RED2022-134750-T). KdlP was supported by the Industrial Ph.D. Doctorate (DIN2018-010094) of the Spanish Ministry of Economy and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Protein-protein binding kinetics by biolayer interferometry, Running title: Binding kinetics by BLI

  • Santos-López, Jorge
  • Gómez, Sara
  • Fernández, Francisco J.
  • Vega, María Cristina
22 p.-3 fig., The specific kinetics and thermodynamics of protein-protein interactions underlie the molecular mechanisms of cellular functions; hence the characterization of these interaction parameters is central to the quantitative understanding of physiological and pathological processes. Many methods have been developed to study protein-protein interactions, which differ in various features including the interaction detection principle, the sensitivity, whether the method operates in vivo, in vitro, or in silico, the temperature control, the use of labels, immobilization, the amount of sample required, the number of measurements that can be accomplished simultaneously, or the cost. Bio-Layer Interferometry (BLI) is a label-free biophysical method to measure the kinetics of protein-protein interactions. Label-free interaction assays are a broad family of methods that do not require protein modifications (other than immobilization) or labels such as fusions with fluorescent proteins or transactivating domains or chemical modifications like biotinylation or reaction with radionuclides. Besides BLI, other label-free techniques that are widely used for determining protein-protein interactions include surface plasmon resonance (SPR), thermophoresis, and isothermal titration calorimetry (ITC), among others., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-BI00 (MCV), the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00 (MCV), grant S2022/BMD-7278 of the Regional Government of Madrid (MCV), the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV), and the CSIC Special Intramural Grant PIE201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad. JSL acknowledges the support of the PhD program in Molecular Biosciences of the Universidad Autónoma de Madrid (UAM) and the Ministry of Education, Culture and Sports of Spain (FPU Grant 17/06090). KdlP acknowledges the support of the PhD program in Biochemistry, Molecular Biology and Biomedicine of the Universidad Complutense de Madrid (UCM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

X-ray crystallography for macromolecular complexes, Running title: XRD for macromolecular complexes

  • Fernández, Francisco J.
  • Querol-García, Javier
  • Navas-Yuste, Sergio
  • Martino, Fabrizio
  • Vega, María Cristina
22 p.-4 fig., X-ray crystallography has for most of the last century been the standard technique to determine the high-resolution structure of biological macromolecules, including multi-subunit protein-protein and protein-nucleic acids as large as the ribosome and viruses. As such, the successful application of X-ray crystallography to many biological problems revolutionized biology and biomedicine by solving the structures of small molecules and vitamins, peptides and proteins, DNA and RNA molecules, and many complexes-affording a detailed knowledge of the structures that clarified biological and chemical mechanisms, conformational changes, interactions, catalysis and the biological processes underlying DNA replication, translation, and protein synthesis. Now reaching well into the first quarter of the twenty-first century, X-ray crystallography shares the structural biology stage with cryo-electron microscopy and other innovative structure determination methods, as relevant and central to our understanding of biological function and structure as ever. In this chapter, we provide an overview of modern X-ray crystallography and how it interfaces with other mainstream structural biology techniques, with an emphasis on macromolecular complexes., This work was supported by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (MCV), the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00 (MCV), grant S2022/BMD-7278 of the Regional Government of Madrid (MCV), the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV), and the CSIC Special Intramural Grant PIE201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Systems immunology: When systems biology meets immunology

  • Alfonso-González, Lucía
  • Fernández, Francisco J
  • Vega, María Cristina
The immune system is an intricate network of cells, proteins, and signaling pathways that coordinate protective responses and, when dysregulated, drive immune-related diseases. Understanding this complexity increasingly relies on systems-based mathematical and computational approaches, which integrate multi-omics data, mechanistic models, and artificial intelligence to reveal the emergent behavior of immune networks. In this mini-review, we discuss the central methodological pillars of systems immunology, including Network Pharmacology, artificial intelligence, and quantitative systems pharmacology. We highlight illustrative applications spanning autoimmune, inflammatory, and infectious diseases, and describe how these methods are used to identify biomarkers, optimize therapies, and guide drug discovery. Finally, we examine current challenges and future directions, including data quality, model validation, and regulatory considerations, which must be addressed to translate systems immunology into clinical impact. This integrated perspective aims to guide both method developers and translational researchers, emphasizing the growing role of computational modeling in next-generation immunology and therapeutic innovation., The author(s) declare financial support was received for the research and/or publication of this article. This work was funded by the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and CPP2022-009838 (FJF and MCV); grant S2022/BMD-7278 of the Regional Government of Madrid (MCV); the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV); and the Instituto de Salud Carlos III (ISCIII) grant PI24/00925 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MCV). LA-G was supported by an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FJF and MCV). The funders had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative (PROA) through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria

  • Rodríguez de Córdoba, Santiago
  • Reparaz, Andrea
  • González Sanz, Silvia
  • Fernández, Francisco J.
  • Vega, María Cristina
  • Varela, Enrique Colado
  • Lada Colunga, Alejandro
  • Vallejo Llamas, Juan Carlos
  • Gonzalez-Rodríguez, Ana Pilar
Paroxysmal nocturnal hemoglobinuria (PNH) is treated with complement inhibitors, yet incomplete responses remain a challenge. Terminal inhibition with eculizumab prevents intravascular hemolysis but often leaves residual extravascular hemolysis, while proximal inhibitors such as pegcetacoplan mitigate extravascular hemolysis though intravascular hemolysis may persist. Understanding resistance mechanisms is critical to guide therapy., The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by a Spanish grant from the Regional Government of Madrid (S2022/BMD-7278), the Instituto de Salud Carlos III (PI23/01576 and PI24/00925) co-funded by the European Union, the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 and CPP2022-009838, Fundación Xti Xtod@s, the Fundación LAIR, the Fundación Alimerka and the Government of the Principality of Asturias through the Agency for Science, Business Competitiveness and Innovation of the Principality of Asturias and co-funded by the European Union, through the Grants for Research Groups of Organizations of the Principality of Asturias for Fiscal Year 2024, with file number IDE/2024/000745. It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative (PROA) through its Unit of Information Resources for Research (URICI)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C-model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system

  • Alfonso-González, Lucía
  • Vega, María Cristina
  • Fernández, Francisco J.
Recently, there has been increased research on treatments that modulate the complement system because of its significance in many diseases. However, managing patients with complement-related diseases is challenging owing to the different responses to treatments because of the heterogeneity of the aetiology of the different diseases, which may affect different proteins of the complement activation cascade. This study addresses these challenges using a comprehensive computational model, C-model., LAG acknowledges the support of the PhD program in Medicinal Chemistry of the Universidad Complutense de Madrid (UCM). This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (MCV); the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and CPP2022-009838 (FJF and MCV); grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid (MCV); the European Commission – NextGenerationEU through CSIC's Global Health Platform (‘PTI Salud Global’) (SGL2103020) (MCV); and the CSIC Special Intramural Grant PIE-201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MCV). We also acknowledge the CSIC Network of Rare Diseases (RER-CSIC). LAG was supported by an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FJF and MCV)., Peer reviewed